Pre-Market Update: CMMB - Breakout on NewsOverview
Looking for an incoming buy-in opportunity on APO - Apollo around the $158-$160 range by mid-February. This setup aligns with a potential longer-term hold and a continuation back to its previous all-time highs (ATHs). If it follows an incremental climb higher, this could yield a 19-20%+ gai
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.89 USD
−14.01 M USD
0.00 USD
16.57 M
About Chemomab Therapeutics Ltd.
Sector
Industry
CEO
Adi Mor
Website
Headquarters
Tel Aviv
Founded
2011
FIGI
BBG00N0PMGK1
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My opinion remains intact about this small bio cap. I will not sell a single share below $40 unless something bad happens, but that does not seem to be the case according to the recent news and reports. The stock has been falling on very low volume. The compan
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My long position on this small bio play remains intact. On the technical side, the stock has been pulling back on low volume to test the breakout zone around the $20 area. If this zone is respected next week, I expect that the next rebound will push the price
CMMBI think Chemomab Therapeutics Ltd (NASDAQ:CMMB) is building a nice base for take off. Some technical indicators are showing positive divergences on a daily basis. We could be in the early stages of a nice rally for this stock. Keep a close eye on it going forward. The stock currently trades at just
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.:
- 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk.
- Bottom of Risk Range:
- S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io
- Cantor Fitzgerald assigned overweight rating on CMMB and r
CMMBI've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices wi
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) This is a stock that I like a lot for another big rally. In the last couple of times it went under $30, the stock had a big spike right after. Don't worry with the SEC Form S-3 filed on Friday, for me means news ahead, before the raise ;) read the market behin
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.